Endogenous insulin secretion even at a very low level contributes to the stability of blood glucose control in fulminant type 1 diabetes
- PMID: 24843445
- PMCID: PMC4014893
- DOI: 10.1111/j.2040-1124.2010.00059.x
Endogenous insulin secretion even at a very low level contributes to the stability of blood glucose control in fulminant type 1 diabetes
Abstract
Fulminant type 1 diabetes is characterized by almost complete β-cell destruction, resulting in scarce insulin secretion. In the present study, we aimed to clarify clinical features related to serum C-peptide levels measured by a high sensitivity method, chemiluminescent enzyme immunoassay, in 12 patients with fulminant type 1 diabetes. Serum C-peptide was detected (0.007-0.10 nmol/L) in four patients and was not detected in eight patients. A negative correlation was observed between serum C-peptide levels and daily dosages of insulin (P < 0.01). The patients with detectable C-peptide showed a significantly lower M-value than those without (P = 0.01). In conclusion, our present results suggest that even very low levels of endogenous insulin secreting capacity can improve daily dosages of insulin and stabilize blood glucose levels. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2010.0059.x, 2010).
Keywords: Fulminant type 1 diabetes; M‐value; Serum C‐peptide.
Figures


Similar articles
-
Correlation of glycated albumin but not hemoglobin A1c with endogenous insulin secretion in fulminant type 1 diabetes mellitus.J Diabetes Investig. 2010 Dec 3;1(6):279-82. doi: 10.1111/j.2040-1124.2010.00050.x. J Diabetes Investig. 2010. PMID: 24843444 Free PMC article.
-
Fulminant type 1 diabetes as a high risk group for diabetic microangiopathy--a nationwide 5-year-study in Japan.Diabetologia. 2007 Mar;50(3):531-7. doi: 10.1007/s00125-006-0575-y. Epub 2007 Jan 18. Diabetologia. 2007. PMID: 17235525
-
CD4⁺ CD45RA⁻ FoxP3high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetes.Clin Exp Immunol. 2013 Aug;173(2):207-16. doi: 10.1111/cei.12116. Clin Exp Immunol. 2013. PMID: 23607886 Free PMC article.
-
Inhibition of glucagon secretion.Adv Pharmacol. 2005;52:151-71. doi: 10.1016/S1054-3589(05)52008-8. Adv Pharmacol. 2005. PMID: 16492545 Review.
-
Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.Dan Med J. 2016 Apr;63(4):B5230. Dan Med J. 2016. PMID: 27034187 Review.
Cited by
-
Relationship of continuous glucose monitoring-related metrics with HbA1c and residual β-cell function in Japanese patients with type 1 diabetes.Sci Rep. 2021 Feb 17;11(1):4006. doi: 10.1038/s41598-021-83599-x. Sci Rep. 2021. PMID: 33597626 Free PMC article.
-
Metabolic signatures of β-cell destruction in type 1 diabetes.J Diabetes Investig. 2023 Jan;14(1):48-57. doi: 10.1111/jdi.13926. Epub 2022 Oct 13. J Diabetes Investig. 2023. PMID: 36227003 Free PMC article.
-
β-Cell failure in diabetes: Common susceptibility and mechanisms shared between type 1 and type 2 diabetes.J Diabetes Investig. 2021 Sep;12(9):1526-1539. doi: 10.1111/jdi.13576. Epub 2021 Jun 16. J Diabetes Investig. 2021. PMID: 33993642 Free PMC article. Review.
-
Analysis of thyroid autoantibodies and the risk of insulin depletion after the clinical onset of acute-onset type 1 diabetes in Japanese patients: the TIDE-J study.Diabetol Int. 2024 Oct 9;16(1):39-49. doi: 10.1007/s13340-024-00764-z. eCollection 2025 Jan. Diabetol Int. 2024. PMID: 39877451
-
A Case of Fulminant Type 1 Diabetes With Residual Insulin Secretion.Cureus. 2025 Apr 21;17(4):e82751. doi: 10.7759/cureus.82751. eCollection 2025 Apr. Cureus. 2025. PMID: 40406776 Free PMC article.
References
-
- American Diabetes Association . Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31: S55–S60 - PubMed
-
- Imagawa A, Hanafusa T, Miyagawa J, et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes‐related antibodies. N Engl J Med 2000; 342: 301–307 - PubMed
-
- Imagawa A, Hanafusa T, Uchigata Y, et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 2003; 26: 2345–2352 - PubMed
-
- Horie M, Ueda K, Shibasaki S, et al. The assessment of low‐dose serum C‐peptide secretion clarified by chemiluminescent enzyme immunoassay and its clinical effectiveness. J Japan Diab Soc 2008; 51: 639–644 (in Japanese).
-
- Hanafusa T, Imagawa A. Fulminant type 1 diabetes: a novel clinical entity requiring special attention by all medical practitioners. Nat Clin Pract Endocrinol Metab 2007; 3: 36–45 - PubMed
LinkOut - more resources
Full Text Sources